Profile data is unavailable for this security.
About the company
Arcticzymes Technologies ASA is a Norway-based holding company providing support functions to the ArcticZymes AS subsidiary including distribution, administration, finance, Information Technology (IT) and quality assurance. As a life science company, Arcticzymes Technologies ASA is focused on the development, manufacturing, and commercialization of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Some of the key features of the Company’s enzymes include cold activeness and salt tolerance. The Company’s divided into two operating segments; Enzymes and Corporate. Arcticzymes established logistic hubs in the United States and the Netherlands to serve its customers more efficiently.
- Revenue in NOK (TTM)103.07m
- Net income in NOK7.66m
- Incorporated1995
- Employees55.00
- LocationArcticzymes Technologies ASASykehusveien 23TROMSO 9019NorwayNOR
- Phone+47 77648900
- Fax+47 77648901
- Websitehttps://arcticzymes.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dicot Pharma AB | 134.14k | -89.42m | 682.38m | 4.00 | -- | 7.10 | -- | 5,087.15 | -0.0459 | -0.0459 | 0.00007 | 0.0449 | 0.001 | 10.68 | 0.0371 | 42,000.00 | -69.50 | -94.78 | -75.43 | -111.46 | -61,341.27 | -32,616.05 | -66,663.49 | -37,576.05 | 8.82 | -- | 0.00 | -- | -88.60 | -47.16 | -30.66 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -84.88m | 781.64m | 10.00 | -- | 6.11 | -- | -- | -5.92 | -5.92 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.19 | -22.82 | -48.56 | -24.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.24 | -- | -- | -- |
| Cinclus Pharma Holding publ AB | 51.55m | -188.48m | 858.09m | 19.00 | -- | 1.91 | -- | 16.65 | -3.80 | -3.80 | 1.04 | 9.07 | 0.0777 | -- | 15.47 | 3,724,539.00 | -28.43 | -- | -32.01 | -- | -- | -- | -365.65 | -- | -- | -- | 0.0197 | -- | -23.14 | -- | 21.89 | -- | -- | -- |
| Vistin Pharma ASA | 454.84m | 78.06m | 940.11m | 77.00 | 12.04 | 3.01 | 9.44 | 2.07 | 1.76 | 1.76 | 10.26 | 7.05 | 1.12 | 1.87 | 6.20 | -- | 19.20 | 1.65 | 23.64 | 1.99 | 66.40 | 62.28 | 17.16 | 1.88 | 1.16 | -- | 0.063 | -- | -1.45 | 13.56 | 37.62 | -1.03 | 17.32 | -- |
| Orexo AB | 411.35m | -214.09m | 1.00bn | 72.00 | -- | 1.91 | -- | 2.43 | -5.80 | 18.42 | 11.15 | 14.22 | 0.4073 | 1.29 | 2.02 | 5,366,667.00 | -21.20 | -28.03 | -29.75 | -42.57 | 89.96 | 83.88 | -52.04 | -74.89 | 3.70 | -3.00 | 0.5005 | -- | -12.46 | -47.69 | 15.63 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -113.14m | 1.06bn | 8.00 | -- | 5.10 | -- | -- | -2.20 | -2.20 | 0.00 | 3.65 | 0.00 | -- | -- | 0.00 | -45.16 | -85.38 | -50.22 | -99.19 | -- | -- | -- | -- | -- | -63.96 | 0.0071 | -- | -- | -- | 61.82 | -- | -- | -- |
| Arcticzymes Technologies ASA | 103.07m | 7.66m | 1.14bn | 55.00 | 152.28 | 3.45 | 69.01 | 11.05 | 0.1464 | 0.1464 | 1.97 | 6.47 | 0.2967 | 0.295 | 1.91 | 1,874,073.00 | 2.20 | 13.28 | 2.32 | 14.39 | 95.42 | 96.20 | 7.43 | 31.41 | 15.45 | -- | 0.0184 | 0.00 | -12.26 | 18.22 | -56.40 | -- | 53.98 | -- |
Data as of Feb 16 2026. Currency figures normalised to Arcticzymes Technologies ASA's reporting currency: Norwegian Krone NOK
6.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Schroder Investment Management (Europe) SA (Finland)as of 30 Jun 2025 | 1.20m | 2.35% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2025 | 629.61k | 1.23% |
| Aktia Bank Plc (Investment Management)as of 31 Oct 2025 | 500.00k | 0.98% |
| Carnegie Fonder ABas of 30 Dec 2025 | 300.00k | 0.59% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 30 Nov 2025 | 261.88k | 0.51% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 195.20k | 0.38% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 84.47k | 0.17% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 17.08k | 0.03% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 2.43k | 0.01% |
| Nordea Investment Management AB (Finland)as of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 28 Nov 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
